Bank Of New York Mellon Corp Lineage Cell Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $72,244 - $106,242	70,828 New	70,828 $82,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $380,876 - $547,509	-340,068 Reduced 82.76%	70,827 $112,000
Q1 2022 May 11, 2022	SELL	$1.21 - $2.48 $12,522 - $25,665	-10,349 Reduced 2.46%	410,895 $633,000
Q4 2021 Feb 11, 2022	SELL	$1.84 - $2.68 $6,927 - $10,090	-3,765 Reduced 0.89%	421,244 $1.03 Million
Q3 2021 Nov 12, 2021	BUY	$2.26 - $2.86 $98,974 - $125,250	43,794 Added 11.49%	425,009 $1.07 Million
Q2 2021 Aug 11, 2021	BUY	$2.17 - $3.0 $669,045 - $924,948	308,316 Added 422.94%	381,215 $1.09 Million
Q1 2021 May 13, 2021	SELL	$1.77 - $3.1 $15,799 - $27,670	-8,926 Reduced 10.91%	72,899 $171,000
Q4 2020 Feb 09, 2021	BUY	$0.95 - $1.83 $2,793 - $5,380	2,940 Added 3.73%	81,825 $144,000
Q2 2020 Aug 12, 2020	SELL	$0.71 - $1.18 $235,436 - $391,288	-331,600 Reduced 80.78%	78,885 $68,000
Q1 2020 May 06, 2020	SELL	$0.6 - $1.58 $51,175 - $134,761	-85,292 Reduced 17.2%	410,485 $340,000
Q4 2019 Feb 14, 2020	BUY	$0.54 - $1.01 $21,629 - $40,454	40,054 Added 8.79%	495,777 $441,000
Q3 2019 Nov 07, 2019	BUY	$0.85 - $1.24 $387,364 - $565,096	455,723 New	455,723 $446,000

134

106M

22.1K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $115M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.